The abstract is read at the publisher; the summary is JClub's.
A human commensal Clostridium immunis prevents and treats obesity in mice by secreting a phosphocholine-modified exopolysaccharide that requires phosphocholine biosynthesis.
- Why it matters: Obesity is a global epidemic partly regulated by the microbiota, but the specific microbial factors and structural motifs controlling immunometabolism were unclear.
- What they did: The study used loss- and gain-of-function mutants targeting the phosphocholine biosynthesis locus (licABC) and tested effects on IL-22 and group 3 innate lymphoid cells in mice.
- The result: The exopolysaccharide lowers small-intestinal and visceral fat by decreasing IL-22, and it fails to act when IL-22 or group 3 innate lymphoid cells are absent; phosphocholine biosynthesis genes are less abundant in humans with obesity or hypertriglyceridemia.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.